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TO THE EDITOR: Intravenous immunoglobulin (IVIG) therapy has gained popularity for the treatment of 
neuromuscular diseases (i.e., myasthenia gravis, inflammatory myopathy, chronic inflammatory 
demyelinating polyneuropathy), although adverse events are associated with high-dose IVIG infusions.1,2 
Common adverse reactions to IVIG therapy are anxiety, headache, fever, chills, chest pain, dyspnea, nausea, 
and abdominal pain.3 More serious adverse events include anaphylaxis, hemolytic anemia, hepatitis C, and 
thrombosis.3 Studies have shown documented effects of IVIG on blood rheology. It increases plasma 
viscosity in a dose-related response and may also activate platelets.2–4 High-dose IVIG therapy is 
approximately 24–54 g/d.4 
Case Report. A 55-year-old white man presented to the emergency department (ED) complaining 
of chest pain and shortness of breath for 5 days in mid-2002. The patient's past medical history 
included sleep apnea, hypertension, deep-vein thrombosis (DVT), peripheral neuropathy, and 
immunosuppressive syndrome. He had no history of diabetes or heart or lung disease, and his 
family history was noncontributory. Current medications included warfarin for treatment of DVT 
caused by Port-A-Cath and IVIG for peripheral neuropathy. He also used 
oxycodone/acetaminophen and amitriptyline as needed. The patient used continuous positive 
airway pressure for sleep apnea. His last IVIG infusion had been administered 7 days prior to the 
ED visit. Abnormal laboratory test findings in ED were international normalized ratio (INR) 1.73 
(normal 2–3), partial thromboplastin time 45.7 seconds (21–35), pH 7.47 (7.36–7.44), and pO2 60 
mmHg (90–100). A computed tomography scan of the chest discovered bilateral pulmonary 
embolism in the right lower and left upper lobes. He was admitted to the hospital with severe 
stenosis extending to the occlusion of the left subclavian vein, and his left inominate vein was 
thrombosed by >5 cm.  
The patient had a history of thrombosis, and now bilateral pulmonary emboli were noted without 
obvious triggering factors. Upon further investigation, we found that the patient had been evaluated 
at another institution for peripheral neuropathy of unknown origin in 2000. He suffered from 
severe burning, tingling, numbness, and pain in his extremities that was incapacitating when he 
was not receiving IVIG. He had developed his first DVT in late 2001. At that time, the patient 
started IVIG infusions twice weekly. Due to cost issues, the infusions were decreased to once a 
week at the beginning of 2002. After evaluating all potential causes for thrombosis, including the 
subtherapeutic INR upon admission, IVIG was determined to be the most probable cause of 
pulmonary embolism according to the Naranjo probability scale,5 and the patient was advised to 
discontinue IVIG therapy. Inpatient treatment for pulmonary embolism included enoxaparin and 
warfarin and, on discharge, the patient was prescribed subcutaneous enoxaparin 100 mg twice 
daily for 7 days and warfarin 7.5 mg 1 day per week and 5 mg on all other days, adjusted to an 
INR goal of 2.5–3.5.  
Discussion. To date, there have been <15 cases reported concerning thrombotic events related to 
IVIG therapy.2 Caution should be used when considering IVIG therapy in the geriatric population 
and patients with known risk factors such as history of pulmonary embolism, DVT, stroke, 
myocardial infarction, cardiac valve replacement, or low cardiac output.1,3 
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